Biopharmaceutical Research Consortium Structure and Governance

CQDM operates through its representative bodies: the Board of Directors and its committees, officers, members and other representatives.

Board of Directors

The Board of Directors and its five sub-committees are largely responsible for the governance of the biopharmaceutical research consortium. Members of the Board meet four times per year and oversee the sound management of the biopharmaceutical research consortium. They ensure that financial matters are dealt with carefully and independently, in compliance with the selection criteria of each funding program maintained by CQDM.

Members of the Board of Directors represent all stakeholders of the biopharmaceutical research consortium and draw on their extensive experience to help CQDM maximize the impact of funded projects and reach its objectives.

Chairman

Richard Fajzel
Chief Executive Officer,
Exactis Innovation

Observers

Martin Houle
Director, Industrial Partnerships,
Quebec Ministry of Economy and Innovation (MEI)

Denis Godin
Associate Vice-President,
Networks of Centres of Excellence

Secretary

François Painchaud 
Lawyer, Partner,
ROBIC, LLP

Members

Jennifer Chan
Vice President, Policy and Communications,
Merck Canada

Diane Gosselin
President and Chief Executive Officer,
CQDM

Daniel Hétu
Managing Director,
Lumira Ventures

Raphael Hofstein
President and Chief Executive Officer,
Toronto Innovation Acceleration Partners (TIAP)

Sarah Jenna
Co-founder and CEO,
My Intelligence Machines (MIMs)

Frédéric Ors
Chief Executive Officer,
IMV

Ken Pastor
General Partner,
CTI Capital

Louise Proulx
Corporate Director

Jorge Puente
Co-Founder and Managing Partner,
Pleasanton Pharma Ventures

Rémi Quirion
Chief Scientist of Quebec

Uwe Schoenbeck
Senior VP & Chief Scientific Officer, External R&D Innovation,
Pfizer worldwide R&D

Patrick J. Wier
Senior Vice President, In Vitro/In Vivo Translation Platform,
GSK

 

Executive Committee

The Executive Committee meets regularly to settle specific aspects of the biopharmaceutical research consortium’s business activities.

Chairman

Richard Fajzel
Chief Executive Officer,
Exactis Innovation

Members

Jennifer Chan
Vice President, Policy and Communications,
Merck Canada

Diane Gosselin
President and Chief Executive Officer,
CQDM

Raphael Hofstein
President and Chief Executive Officer,
Toronto Innovation Acceleration Partners (TIAP)

Audit Committee

The Audit Committee is a sub-committee of the Board that meets at least twice per year to review the financial statements and receive notification of any errors or misstatements contained in financial statements from the external auditors.

Chairman

Ken Pastor
General Partner,
CTI Capital

Membre

Domenic De Luca
President,
Managesco Inc.

Richard Fajzel
Chief Executive Officer,
Exactis Innovation

Corporate Governance and Nominating Committee

The Corporate Governance and Nominating Committee ensures that the best resources and members are supporting the structure and governance of the biopharmaceutical research consortium.
The Committee oversees the recruitment, resignation and replacement process of new Board members. Its ultimate goal is to help CQDM focus on executing its strategy, while leveraging the experience of the Board.

Chairman

Richard Fajzel
Chief Executive Officer,
Exactis Innovation

Members

Jennifer Chan
Vice President, Policy and Communications,
Merck Canada

Raphael Hofstein
President and Chief Executive Officer,
Toronto Innovation Acceleration Partners (TIAP)

Diane Gosselin
President and Chief Executive Officer,
CQDM

Scientific Advisory Board

The Scientific Advisory Board was created by the Board of Directors and is comprised of experienced and independent scientists. The members examine all external scientific reviews obtained by CQDM, ensure that projects targeted for funding meet all selection criteria and present their recommendations to the Board of Directors. The Scientific Advisory Board is the reason why CQDM can testify that it maintains a stringent selection process that maximizes positive R&D impacts for its members.

Chairman

Daniel Hétu
Managing Director,
Lumira Capital

Observers

Monika Michalska
Senior Program Manager,
Networks of Centres of Excellence

Catherine Richard
Advisor, Industrial Partnerships,
Quebec Ministry of Economy and Innovation (MEI)

Diane Gosselin
President and Chief Executive Officer,
CQDM

Members

André Darveau
Vice Rector, Administration,
Université Laval

Mark Lim
Assistant Director, International Affairs,
American Society for Microbiology

Philippe Walker
President,
PW Consulting

Brian Underdown
Biotechnology Consultant,
BJUConsulting